中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 6
Jun.  2016
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2016  >  32(6): 1079-1082

Research advances in computed tomography and magnetic resonance imaging findings of cirrhotic portal hypertension

DOI: 10.3969/j.issn.1001-5256.2016.06.011
  • Published Date: 2016-06-20
    Abstract
  • Portal hypertension is the most common complication of liver cirrhosis.Noninvasive radiological examinations have important values in evaluating liver parenchyma,collateral circulation,and esophagogastric variceal bleeding in liver cirrhosis.Computed tomography(CT) and magnetic resonance imaging(MRI) can reflect the changes in liver morphology,the density and signals of liver parenchyma,and hemodynamics and have important values in disease diagnosis and prognostic evaluation.CT and functional MRI,such as perfusion- weighted imaging,MR elastography,and MR diffusion- weighted imaging,can provide quantitative information and can be applied in the diagnosis of hepatic fibrosis and early- stage liver cirrhosis in clinical practice.CT angiography and MR angiography,especially unenhanced MR angiography,can show the condition of the branches of portal vein,which helps to evaluate the risk of esophagogastric variceal bleeding and detect the markers for early warning.A combination of CT and MRI and evaluation of their potential in clinical application can give full play to the role of radiological examinations in the diagnosis,evaluation,and prognostic analysis of cirrhotic portal hypertension.

     

    • FullText(HTML)
    • References(25)
  • [1] BARR DC,HUSSAIN HK.MR imaging in cirrhosis and hepatocellular carcinoma[J].Magn Reson Imaging Clin N Am,2014,22(3):315-335.
    [2] FARIA SC,GANESAN K,MWANGI I,et al.MR imaging of liver fibrosis:current state of the art[J].Radiographics,2009,29(6):1615-1635.
    [3]LONG LL,HUANG ZK,DING K,et al.The value of multi-slice spiral CT liver perfusion imaging to evaluate the chronic hepatic fibrosis and cirrhosis[J].Chin J Radiol,2012,46(4):317-321.(in Chinese)龙莉玲,黄仲奎,丁可,等.多层螺旋CT肝脏灌注成像评价慢性肝纤维化、肝硬化的价值[J].中华放射学杂志,2012,46(4):317-321.
    [4] HAGIWARA M,RUSINEK H,LEE VS,et al.Advanced liver fibrosis:diagnosis with 3D whole---liver perfusion MR imaging-initial experience[J].Radiology,2008,246(3):926-934.
    [5]KIM D,KIM WR,TALWALKAR JA,et al.Advanced fibrosis in nonalcoholic fatty liver disease-noninvasive assessment with MRelastography[J].Radiology,2013,268(2):411-419.
    [6] LOOMBA R,WOLFSON T,ANG B,et al.Magnetic Resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease a prospective study[J].Hepatology,2014,60(6):1920-1928.
    [7] YOON JH,LEE JM,JOO I,et al.Hepatic fibrosis:prospective comparison of MR elastography and us shear-wave elastography for evaluation[J].Radiology,2014,273(3):772-782.
    [8] HANNA RF,AGUIRRE DA,KASED N,et al.Cirrhosis-associated hepatocellular nodules-correlation of histopathologic and MRimaging features[J].Radiographics,2008,28(3):747-769.
    [9] HUSSAIN SM,REINHOLD C,MITCHELL DG.Cirrhosis and lesion characterization at MR imaging[J].Radiographics,2009,29(6):1637-1652.
    [10]YAN FH,ZHOU KR,SHEN JZ,et al.Comparason of enhancement patterns of multi-phase scan of dynamic MRI and dynamic CT in small hepatocellular carcinoma[J].Chin J Oncol,2001,23(5):413-416.(in Chinese)严福华,周康荣,沈继章,等.MR和CT动态扫描对小肝癌强化特征的比较研究[J].中华肿瘤杂志,2001,23(5):413-416.
    [11]YAN FH,ZHOU KR,WU D,et al.Evaluation of dynamic enhanced fast multiplanar spoiling gradient recalled(FMPSPGR)in the diagnosis of small hepatocellular carcinoma[J].Chin J Hepatol,2001,9(3):139-141.(in Chinese)严福华,周康荣,吴东,等.快速多层面干扰梯度回波序列动态增强扫描在小肝癌诊断中的价值评估[J].中华肝脏病杂志,2001,9(3):139-141.
    [12]XU PJ,YAN FH,WANG JH,et al.The value of breath-hold diffusion-weighted imaging in small hepatocellular carcinoma lesion(≤3cm)detection[J].Natl Med J China,2009,89(9):592-596.(in Chinese)徐鹏举,严福华,王建华,等.弥散加权成像对肝细胞癌小病灶检测的价值[J].中华医学杂志,2009,89(9):592-596.
    [13]XU PJ,YAN FH,WANG JH,et al.The comparative study of diffusion-weighted MR imaging with modified sensitivity encoding technique for small hepatocellular carcinoma lesions[J].Chin J Radiol,2007,41(1):5-9.(in Chinese)徐鹏举,严福华,王建华,等.改良敏感编码技术在肝脏MR扩散加权成像中对肝细胞癌小病灶的影响[J].中华放射学杂志,2007,41(1):5-9.
    [14] PARK MJ,KIM YK,LEE MW,et al.Small hepatocellular carcinomas:improved sensitivity by combining ga-doxetic acid-enhanced and diffusion-weighted MR imaging patterns[J].Radiology,2012,264(3):761-770.
    [15] LIU X,ZOU L,LIU F,et al.Gadoxetic acid disodium-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma:a meta-analysis[J].PLo S One,2013,8(8):e70896.
    [16] CHOI JY,LEE JM,SIRLIN CB.CT and MR imaging diagnosis and staging of hepatocellular carcinoma:part II.Extracellular agents,hepatobiliary agents,and ancillary imaging features[J].Radiology,2014,273(1):30-50.
    [17]LEE JY,KIM TY,JEONG WK,et al.Clinically severe portal hypertension:role of multi-detector row CT features in diagnosis[J].Dig Dis Sci,2014,59(9):2333-2343.
    [18] KANG HK,JEONG YY,CHOI JH,et al.Three-dimensional multi-detector row CT portal venography in the evaluation of portosystemic collateral vessels in liver cirrhosis[J].Radiographics,2002,22(5):1053-1061.
    [19]ZHU H,SHI B,UPADHYAYA M,et al.Therapeutic endoscopy of localized gastric varices:pretherapy screening and posttreatment evaluation with MDCT portography[J].Abdom Imaging,2010,35(1):15-22.
    [20]WANG F,SHEN JL,HUA J,et al.A study of applications of spectral CT in predicting the risk of variceal bleeding of liver cirrhosis with portal hypertension[J].Radiol Pract,2015,30(7):763-767.(in Chinese)王芳,沈加林,华静,等.能谱CT在预测肝硬化门脉高压食管静脉曲张出血风险的应用[J].放射学实践,2015,30(7):763-767.
    [21] ANNET L,MATERNE R,DANSE E,et al.Hepatic flow parameters measured with MR imaging and Doppler US:correlations with degree of cirrhosis and portal hypertension[J].Radiology,2003,229(2):409-414.
    [22] ANNET L,PEETERS F,HORSMANS Y,et al.Esophageal varices:evaluation with transesophageal MR imaging--initial experience[J].Radiology,2006,238(1):167-175.
    [23] SHIN SU,LEE JM,YU MH,et al.Prediction of esophageal varices in patients with cirrhosis:usefulness of three-dimensional MRelastography with echo-planar imaging technique[J].Radiology,2014,272(1):143-153.
    [24] GOUYA H,VIGNAUX O,SOGNI P,et al.Chronic liver disease:systemic and splanchnic venous flow mapping with optimized cine phase-contrast MR imaging validated in a phantom model and prospectively evaluated in patients[J].Radiology,2011,261(1):144-155.
    [25] GOUYA H,GRABAR S,VIGNAUX O,et al.Portal hypertension in patients with cirrhosis:indirect assessment of hepatic venous pressure gradient by measuring azygos flow with 2D-cine phase-contrast magnetic resonance imaging[J].Eur Radiol,2015.[Epub ahead of print]
    • Relative Articles

  • Relative Articles

    [1]Meng PeiPei, Liu Yao, Zhou MeiYue, Yu Hao, Yang YuYing, Jiang YuYong. Effect of anti-liver fibrosis Chinese patent drugs in preventing renal hypofunction associated with alcoholic liver disease[J]. Journal of Clinical Hepatology, 2020, 36(9): 2030-2034. doi: 10.3969/j.issn.1001-5256.2020.09.024
    [2]Chen HaiZhen, Huang Jing. Research advances in antioxidants in the progression of alcoholic liver disease[J]. Journal of Clinical Hepatology, 2019, 35(12): 2817-2819. doi: 10.3969/j.issn.1001-5256.2019.12.038
    [3]Cao HaiXia, Fan JianGao. Alcoholic liver disease with nonalcoholic fatty liver disease and obesity[J]. Journal of Clinical Hepatology, 2019, 35(3): 478-480. doi: 10.3969/j.issn.1001-5256.2019.03.005
    [4]Liu Chen, Xing HuiChun, Cheng Jun, Yang Song. Influence of drinking on progression of chronic hepatitis B and outcome of antiviral therapy[J]. Journal of Clinical Hepatology, 2019, 35(3): 472-475. doi: 10.3969/j.issn.1001-5256.2019.03.003
    [5]Li Wei, Xing HuiChun. Intestinal microflora and alcoholic liver disease[J]. Journal of Clinical Hepatology, 2019, 35(3): 481-484. doi: 10.3969/j.issn.1001-5256.2019.03.006
    [6]Yang Jun, Hu ZhongJie, Zhu YueKe, Yu HongWei, Li Juan, Hou Wei, Ning QiQi. Clinical effect of glucocorticoids versus pentoxifylline in patients with severe alcoholic liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(7): 1546-1550. doi: 10.3969/j.issn.1001-5256.2019.07.025
    [7]Li ZhiGuo, Zhu Shun, Li Shuo, Ye YongAn. Recommendations for diagnosis and treatment of alcohol-related liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases[J]. Journal of Clinical Hepatology, 2019, 35(11): 2447-2448. doi: 10.3969/j.issn.1001-5256.2019.11.011
    [8]Fatty Liver Expert Committee，Chinese Medical Doctor Association, National Workshop on Fatty Liver and Alcoholic Liver Disease，Chinese Society of Hepatology，Chinese Medical Association. Guidelines of prevention and treatment for alcoholic liver disease:a 2018 update[J]. Journal of Clinical Hepatology, 2018, 34(5): 939-946. doi: 10.3969/j.issn.1001-5256.2018.05.006
    [9]Yang FuNing, Huang Jing. Research progress in genetic susceptibility to alcoholic liver disease[J]. Journal of Clinical Hepatology, 2017, 33(2): 379-383. doi: 10.3969/j.issn.1001-5256.2017.02.039
    [10]Gao GuangFu, Zhang ShuFeng, Wang ZhangWu, Gao HongWei. Clinical features of alcoholic liver disease: a clinical analysis of 206 cases[J]. Journal of Clinical Hepatology, 2017, 33(9): 1766-1768. doi: 10.3969/j.issn.1001-5256.2017.09.028
    [11]Cai Qi, Yan WeiWei, Wang ShaoKun, Wu Yang. Protective effect of Cordyceps militaris polypeptide against acute alcoholic liver injury in rats[J]. Journal of Clinical Hepatology, 2016, 32(4): 669-672. doi: 10.3969/j.issn.1001-5256.2016.04.011
    [12]Zhao XueKe, Mu Mao, Cheng MingLiang. Alcoholic liver disease and oxidative stress[J]. Journal of Clinical Hepatology, 2014, 30(2): 118-120. doi: 10.3969/j.issn.1001-5256.2014.02.005
    [13]Chang BinXia, Wang Hua, Zou ZhengSheng, Li BaoSen, Gao Bin. Pathogenesis and novel therapeutic targets of alcoholic liver disease[J]. Journal of Clinical Hepatology, 2014, 30(2): 113-117. doi: 10.3969/j.issn.1001-5256.2014.02.004
    [14]Tao Li, Chen Xi. Role of endoplasmic reticulum stress in pathogenesis of alcoholic liver disease[J]. Journal of Clinical Hepatology, 2013, 29(7): 547-549. doi: 1001-5256 (2013) 07-0547-03
    [15]Li XueHua, Wang BingYuan. Consensus and differences of the three guidelines for the diagnosis of alcoholic liver disease[J]. Journal of Clinical Hepatology, 2012, 28(8): 569-570.
    [16]Qiao ChunPing, Chen YueXiang. Advances in study of the relationship between apoptosis and alcoholic liver disease[J]. Journal of Clinical Hepatology, 2012, 28(5): 386-390.
    [17]Liu XiangYing, Zhang Yi. Analysis of clinical characteristics of alcoholic liver disease cases infected with hepatitis viruses[J]. Journal of Clinical Hepatology, 2012, 28(4): 299-301.
    [18]Ceng MinDe. Introduction to the EASL Clinical Practical Guidelines: Management of alcoholic liver disease[J]. Journal of Clinical Hepatology, 2012, 28(8): 565-568.
    [19]Ge HongYan, Chen Bo, Li YouTian. Protective effects of saikoside on rats with alcoholic liver disease[J]. Journal of Clinical Hepatology, 2012, 28(12): 945-947.
    [20]Gong YuanYing. A clinical observation on metadoxine combined with tiopronin in the treatment of patients with alcoholic liver disease[J]. Journal of Clinical Hepatology, 2012, 28(1): 48-49+52.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(15)

    1. 林锦燕，缪晓峰. 治疗非酒精性脂肪性肝病应用熊去氧胆酸的临床效果分析. 中外医疗. 2022(14): 103-106 .
    2. 李术先，张志勇，赵红心，姚志山. 清肝化湿活血汤联合水飞蓟宾胶囊治疗酒精性肝病临床观察. 中国药业. 2021(08): 64-67 .
    3. 吴云，姚志山，王巍，张文静，张志勇. 酒精性肝病患者中医体质分布特点及证型分布研究. 河北中医. 2021(01): 25-28+33 .
    4. 张文静，吴云，姚志山. 清肝化湿活血汤佐治酒精性肝病临床观察. 中国药业. 2021(16): 105-107 .
    5. 张冬. 加减清肝化湿活血汤联合多烯磷脂酰胆碱在酒精性脂肪肝患者中的应用. 中国当代医药. 2021(22): 208-211 .
    6. 丁彬彬. 还原型谷胱甘肽(GSH)针剂对酒精性肝病的疗效和安全性. 当代医学. 2020(09): 54-56 .
    7. 姚志山，吴云，赵红心，李术先. 中医药治疗酒精性肝病研究进展. 河南中医. 2020(12): 1941-1944 .
    8. 鲍旭. 酒精性肝病的治疗进展. 基层医学论坛. 2019(32): 4705-4707 .
    9. 陈康. 多烯磷脂酰胆碱联合还原型谷胱甘肽对酒精性肝病患者肝功能的影响. 中国处方药. 2019(11): 80-81 .
    10. 敖斯琴. 蒙药清肝九味散对酒精性肝炎患者的治疗作用分析. 健康之路. 2018(07): 205 .
    11. 张萍，张良祥. 高压氧对运动疲劳小鼠肝脏组织抗氧化能力和ATP酶代谢的影响. 吉林大学学报(医学版). 2018(06): 1200-1204 .
    12. 杨逸淦. 酒精性肝病的中医药治疗进展. 内蒙古中医药. 2017(15): 123-124 .
    13. 王耕，周波. 养营活血汤对肝纤维化大鼠NF-kB mRNA表达的影响. 世界最新医学信息文摘. 2017(03): 1-2 .
    14. 张锋. 益肝退黄汤联合脂溶性维生素治疗酒精性肝病伴肝内胆汁淤积疗效及对血清甘胆酸、结合胆汁酸和sVCAM-1水平的影响. 现代中西医结合杂志. 2017(30): 3365-3367 .
    15. 钟之洲，郁清琳. 醒脾养肝汤治疗酒精性肝病对肝功能、肝纤维化相关指标的影响. 中华中医药学刊. 2017(03): 752-754 .

    Other cited types(3)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 2.4 %FULLTEXT: 2.4 %META: 93.3 %META: 93.3 %PDF: 4.4 %PDF: 4.4 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 7.4 %其他: 7.4 %其他: 0.9 %其他: 0.9 %Baden: 0.1 %Baden: 0.1 %Canada: 0.1 %Canada: 0.1 %China: 0.4 %China: 0.4 %Lithonia: 0.1 %Lithonia: 0.1 %Nahant: 0.1 %Nahant: 0.1 %Singapore: 0.2 %Singapore: 0.2 %United States: 0.1 %United States: 0.1 %[]: 0.2 %[]: 0.2 %三门峡: 0.1 %三门峡: 0.1 %上海: 5.5 %上海: 5.5 %东京: 0.2 %东京: 0.2 %东莞: 0.2 %东莞: 0.2 %东营: 0.1 %东营: 0.1 %中卫: 0.1 %中卫: 0.1 %丽水: 0.1 %丽水: 0.1 %佛山: 0.3 %佛山: 0.3 %佛罗里达州: 0.1 %佛罗里达州: 0.1 %北京: 9.1 %北京: 9.1 %匹兹堡: 0.1 %匹兹堡: 0.1 %南京: 0.7 %南京: 0.7 %南宁: 1.2 %南宁: 1.2 %南昌: 0.1 %南昌: 0.1 %卡马里奥: 0.1 %卡马里奥: 0.1 %厦门: 0.2 %厦门: 0.2 %台北: 0.1 %台北: 0.1 %台州: 0.3 %台州: 0.3 %合肥: 0.2 %合肥: 0.2 %吉林: 0.4 %吉林: 0.4 %呼和浩特: 0.1 %呼和浩特: 0.1 %咸阳: 0.1 %咸阳: 0.1 %固原: 0.1 %固原: 0.1 %大庆: 0.2 %大庆: 0.2 %大连: 0.1 %大连: 0.1 %天津: 0.3 %天津: 0.3 %威海: 0.1 %威海: 0.1 %安康: 0.1 %安康: 0.1 %安顺: 0.1 %安顺: 0.1 %宿迁: 0.1 %宿迁: 0.1 %常德: 0.1 %常德: 0.1 %平顶山: 0.1 %平顶山: 0.1 %广州: 0.6 %广州: 0.6 %张家口: 2.2 %张家口: 2.2 %张家界: 0.1 %张家界: 0.1 %徐州: 0.3 %徐州: 0.3 %悉尼: 0.1 %悉尼: 0.1 %惠州: 0.2 %惠州: 0.2 %成都: 1.1 %成都: 1.1 %拉雷多: 0.1 %拉雷多: 0.1 %无锡: 0.1 %无锡: 0.1 %昆明: 0.4 %昆明: 0.4 %昌吉: 0.1 %昌吉: 0.1 %曲靖: 0.1 %曲靖: 0.1 %朝阳: 0.2 %朝阳: 0.2 %杭州: 1.3 %杭州: 1.3 %桂林: 0.1 %桂林: 0.1 %武汉: 0.3 %武汉: 0.3 %汕头: 0.2 %汕头: 0.2 %沈阳: 0.3 %沈阳: 0.3 %洛阳: 0.1 %洛阳: 0.1 %济南: 0.2 %济南: 0.2 %海口: 0.1 %海口: 0.1 %深圳: 0.2 %深圳: 0.2 %温州: 0.1 %温州: 0.1 %湖州: 0.2 %湖州: 0.2 %湘潭: 0.1 %湘潭: 0.1 %湛江: 0.1 %湛江: 0.1 %潍坊: 0.3 %潍坊: 0.3 %牡丹江: 0.2 %牡丹江: 0.2 %珠海: 0.1 %珠海: 0.1 %眉山: 0.3 %眉山: 0.3 %石家庄: 0.3 %石家庄: 0.3 %福州: 0.4 %福州: 0.4 %秦皇岛: 0.1 %秦皇岛: 0.1 %红河: 0.1 %红河: 0.1 %绍兴: 0.1 %绍兴: 0.1 %芒廷维尤: 33.5 %芒廷维尤: 33.5 %芝加哥: 0.3 %芝加哥: 0.3 %苏州: 0.2 %苏州: 0.2 %莫斯科: 1.3 %莫斯科: 1.3 %衡水: 0.1 %衡水: 0.1 %衡阳: 0.1 %衡阳: 0.1 %衢州: 0.2 %衢州: 0.2 %西宁: 16.7 %西宁: 16.7 %西安: 0.5 %西安: 0.5 %赤峰: 0.1 %赤峰: 0.1 %运城: 0.2 %运城: 0.2 %连云港: 0.1 %连云港: 0.1 %遂宁: 0.1 %遂宁: 0.1 %郑州: 0.1 %郑州: 0.1 %重庆: 1.2 %重庆: 1.2 %银川: 0.2 %银川: 0.2 %长春: 0.6 %长春: 0.6 %长沙: 2.5 %长沙: 2.5 %长治: 0.1 %长治: 0.1 %阿坝: 0.1 %阿坝: 0.1 %青岛: 0.8 %青岛: 0.8 %香港: 0.1 %香港: 0.1 %其他其他BadenCanadaChinaLithoniaNahantSingaporeUnited States[]三门峡上海东京东莞东营中卫丽水佛山佛罗里达州北京匹兹堡南京南宁南昌卡马里奥厦门台北台州合肥吉林呼和浩特咸阳固原大庆大连天津威海安康安顺宿迁常德平顶山广州张家口张家界徐州悉尼惠州成都拉雷多无锡昆明昌吉曲靖朝阳杭州桂林武汉汕头沈阳洛阳济南海口深圳温州湖州湘潭湛江潍坊牡丹江珠海眉山石家庄福州秦皇岛红河绍兴芒廷维尤芝加哥苏州莫斯科衡水衡阳衢州西宁西安赤峰运城连云港遂宁郑州重庆银川长春长沙长治阿坝青岛香港

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2901) PDF downloads(525) Cited by(18)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2183]YesterdayPV[4802]TodayIP[190]TodayPV[343]Online[20]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return